SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is surging after positive earnings, fueled by confirmation that Macquarie financing unlocks significant capital without dilution, potentially triggering a short squeeze as shorts bet against their ability to fund expansion. The community is actively discussing price targets and the potential for a gamma squeeze, driven by high short interest and institutional validation from Macquarie. With strong guidance and hyperscaler approvals in place, APLD is gaining momentum as a key player in AI infrastructure.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to its partnership to develop quantum-resistant chips for U.S. defense, fueling speculation about government contracts. The community is discussing its potential for significant growth and comparing it favorably to other quantum stocks. Many believe LAES is undervalued and poised for a substantial run, possibly reaching double digits soon.

One and one Green Technologies. Inc - Ordinary Shares - Class A

YDDL is trending due to its recent IPO and subsequent after-hours surge, fueled by its low float and significant insider ownership. Community members are discussing potential for continued momentum and comparing it to other AI and low-float stocks, while also noting its association with waste management in the Philippines. Traders are watching for potential scalping opportunities, halt patterns, and VWAP reclaims.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as community members discuss its breakout potential and momentum in the automation space, drawing comparisons to Palantir. Some traders are pointing to strong call volume and AI tailwinds as potential catalysts, while others highlight the company's partnerships and potential for a short squeeze. The stock's potential in the AI infrastructure wave is also fueling bullish sentiment.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

ORBS is trending as traders discuss recent price volatility and potential catalysts. Community members are debating whether the stock's pullback presents a buying opportunity, while also speculating about news related to Worldcoin and upcoming events involving Dan Ives. Some traders suggest a potential squeeze given the small float, while others express concern about potential dilution.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending as investors discuss its potential for a short squeeze, fueled by high short interest and recent institutional investment. Community members are also excited about the company's vision and potential connection to clean-energy nuclear reactors for AI infrastructure. The stock is gaining attention as discussions around TeraWulf's pivot towards AI and high-performance computing data centers intensifies, with some comparing it to sector peers.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential for significant growth, with some drawing comparisons to IREN and anticipating a run to higher price levels. Chatter revolves around a possible short squeeze, upcoming news related to AI/HPC, and the company's strong position in the Bitcoin mining sector amid rising cryptocurrency prices. Some are also following news of executive networking and potential government partnerships.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate whether its valuation is justified amidst a significant rally, with some pointing to the potential for a short squeeze and others warning of an impending correction. Bullish sentiment focuses on the future of quantum computing, while bears highlight the company's current financials and question its high market capitalization. Some traders are closely watching for a potential offering, believing it could impact the stock's trajectory.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as chatter increases about its merger with Infleqtion, a quantum computing company, with comparisons being drawn to sector peers like $NVDA. Community members highlight Infleqtion's existing government contracts and potential for growth, viewing the stock as undervalued relative to competitors and pointing to a potential 10X run. Discussions also include the warrants ($CCCXW) as a means for maximizing potential gains.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors digest various factors, including potential settlements in EU antitrust cases, ongoing legal battles concerning child safety and platform addiction, and analyst target price adjustments. The community is closely watching technical indicators and discussing potential for a pre-earnings run-up, with some highlighting the stock's oversold conditions and others expressing concerns about AI spending and market manipulation. Also, the stock's reaction to potential monetary policy changes is being discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding strategies for its development.TZLS-501 is a fully human anti-IL-6 receptor monoclonal antibody or a biological therapy that blocks the action of interleukin-6 protein. Tiziana <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-advance-tzls-501-its-fully-human-il-6r-monoclonal">sees</a> potential to develop it as a monotherapy or in combination with its lead candidate, as well as with other anti-inflammatory and anti-infective agents.The company stated that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions where excessive IL-6 signaling plays a central role, such as rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various types of cancer.The company also stated that it will continue to advance intranasal Foralumab as its lead program, not diverting resources or focus from it. The firm is currently evaluating Foralumab in the treatment of multiple sclerosis, a chronic autoimmune disease in which the immune system attacks the protective myelin sheath surrounding nerve cells in the brain and spinal cord, causing numbness, vision problems, muscle weakness, balance issues, and fatigue.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLSA">TLSA stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:573/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_1_37_07_PM_png_487989b630.webp" alt="TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="573" height="66"><figcaption>TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that the stock has “so much potential.”<stembedurl>https://stocktwits.com/GoCubsGo1124/message/629975723</stembedurl>Tiziana said on Thursday that the <a href="https://stocktwits.com/news-articles/markets/equity/tourmaline-stock-rockets-pre-market-after-novartis-buy-out-announcement/chwKP7BRdt5">recent acquisition</a> of Tourmaline Bio by Novartis for about $1.4 billion validates the importance of IL-6 therapeutics. The acquisition, announced earlier in September, includes Tourmaline’s Pacibekitug, a monoclonal antibody that targets IL-6, which is being evaluated as a treatment option for atherosclerotic cardiovascular disease.“With recent market developments, we feel it is an opportune time to explore TZLS-501’s development,” said Tiziana CEO Ivor Elrifi.TLSA stock nearly tripled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-terminates-study-of-bimagrumab-in-obesity/chDlEmYR34I">Eli Lilly Terminates A Study Of Bimagrumab In Obesity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.

Equity

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.


AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Tiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer's

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer's disease (AD) and Parkinson's disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...

Tiziana Life Sciences announces updated clinical, PET scan findings

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough neuro-immunomodulation therapies...

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies, today...

Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation

Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation...

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

TLSA
Tiziana Life Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TLSA News

TLSATiziana Life Sciences Ltd